Business Wire

Lumen Metabolic Health Device Now Peer-reviewed

Share

Lumen , a health tech company and the creators of the world's first portable metabolism measurement device, has officially been peer-reviewed and published in the Interactive Journal of Medical Research (I-JMR). In collaboration with San Francisco State University, Lumen has validated an ongoing study launched in 2020, which shows the validity of Lumen® to detect changes in metabolic fuel utilization in a comparable manner with a laboratory standard metabolic cart, providing the ability for real-time metabolic information for users under any circumstances.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210517005774/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Lumen now peer-reviewed (Photo: Business Wire)

Developed through years of scientific testing and validation, Lumen is the first handheld, portable device and app that measures your metabolism in real-time with just your breath.

The methodology behind the peer-reviewed validation of Lumen

The study compares the metabolic fuel measurement capabilities of the Lumen device to the gold standard measurement of metabolic carts. These measure the carbon dioxide and oxygen produced from the breath in order to assess metabolic fuel usage (carbohydrates vs. fats). Metabolic carts are known to be costly and only available to the public in laboratory settings.

Lumen has made metabolic testing accessible as the only handheld device available to measure your metabolism from home via the CO2 exhaled from the breath.

"We are thrilled the scientific community recognizes Lumen's ability to measure metabolic fuel utilization as effectively as the metabolic cart. This is groundbreaking because now metabolism measurement is accessible to all from home, rather than relying on solutions that are costly or time-consuming,” says Dr. Shlomo Yeshurun , Head of Research at Lumen.

Results using Lumen and the metabolic cart with young, healthy participants

Participants were young and healthy adults that measured their metabolism at a resting state and in two conditions: fasted and after consuming 150 grams of glucose.

Together with the values obtained from the metabolic cart and data from the Lumen device, changes in metabolic fuel usage were identified.

Both the RER and Lumen CO2 percentage increased significantly after glucose was consumed compared to the fasting state.

Another impactful result indicated that Lumen is in agreement with the gold-standard metabolic cart.

Conclusions

Lumen has the capability to provide accurate information regarding the metabolic state of individuals in agreement with results from the metabolic cart. For the first time, metabolic measurements can be performed from home without the constraints of a laboratory. What was once available only to athletes and medical professionals is now available to all consumers choosing the path to metabolic health.

Lumen plans to continue pioneering metabolic technology, data and knowledge through groundbreaking research and innovative technology to help people achieve optimal health.

The research behind metabolic flexibility

Research (Calcada et al, Gormsen et al) finds that having a flexible metabolism has a profound role in assessing a person's long-term health. People with good metabolic flexibility:

  • Are at lower risk of developing obesity, diabetes and metabolic disorders.
  • Are in a better position to gain muscle and perform better during workouts;
  • Find it easier to lose weight and maintain it

About Lumen

Lumen helps people improve their health and fitness through technology on the forefront of personalized nutrition and metabolism. Conceived and designed by twin sisters, physiology PhDs and Ironman winners, Lumen harnesses the power of our breath to measure metabolism, which is closely linked to weight, fitness and personal health. The Lumen device measures metabolism in a single breath, in less than a minute, which previously was only possible through an hour-long lab test. Available at Lumen.me, Lumen devices ship globally, with the app available on the Apple App Store and Google Play. Lumen is headquartered in Israel, with offices in the United States.

Availability

The Lumen device is available at Lumen.me, currently priced at $299.

The device comes equipped with a travel case, charging dock, USB-C Cable, and Premium Customer Support. Users can download the app for free on the Apple App Store and on Google Play.

For media: images, video and fact sheet can be found in the press kit here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media contact:
Kyla Blumenfeld, press@lumen.me

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bureau Veritas: Strong Start to the Year; 2024 Outlook Confirmed25.4.2024 09:20:00 CEST | Press release

Q1 2024 Key figures1 › Revenue of EUR 1,439.5 million in the first quarter of 2024, up 2.5% year-on-year and up 8.0% organically › Strong organic growth from Industry +16.3%, Certification +13.7%, Marine & Offshore +13.6%, compared to the first quarter of 2023; growth of +6.1% for Consumer Products Services, +3.6% for Buildings & Infrastructure and +3.2% for Agri-food & Commodities › The scope effect was a positive 0.1%, reflecting bolt-on acquisitions offset by a small disposal › The currency impact was negative by 5.6% mainly due to the depreciation of some emerging countries’ currencies against the euro Q1 2024 Highlights › New strategy LEAP | 28, announced on March 20, 2024, to deliver a step change in growth and performance, built around three pillars: Focused Portfolio, Performance-led execution and Evolved People model › Strong growth in every region (Americas, Middle East, Africa, Asia-Pacific and Europe), outperforming many underlying markets › Growth momentum maintained for s

New CPS Protection Platform: TXOne Networks Presents SageOne in Hannover25.4.2024 09:04:00 CEST | Press release

TXOne Networks, a leading company in the field of cyber-physical systems (CPS) security, will be presenting its new CPS security platform during the Hannover Messe from 22nd to 26th April 2024 at stand B06 in hall 16: SageOne, which means Wise Man Number One. This central management console provides an overview of the CPS attack surface of the OT environment. All three TXOne product lines can be centrally controlled, namely Stellar for endpoint protection, Element for security inspection and Edge for network defense. The platform offers integrated OT security across the entire lifecycle of the objects to be protected and enables reliable detection and response to threats. SageOne essentially covers three main pillars: CPS Attack Surface Management: Visibility is a cornerstone for cybersecurity. A clear view of the overall security posture helps identify security focal points in an OT environment. SageOne focuses on operational security by honing in on assets and illuminating the securi

Infobip becomes an Oracle Independent Software Vendor partner25.4.2024 09:00:00 CEST | Press release

Infobip, a global cloud communications platform and a member of Oracle PartnerNetwork (OPN), today announced it has enhanced its relationship with Oracle, becoming an Independent Software Vendor (ISV) with access to Oracle Integration Cloud. Businesses using any Oracle solution can access Infobip’s omnichannel platform through Oracle Cloud Marketplace (OCM). They can quickly orchestrate powerful interactions, help increase customer satisfaction, boost sales, and improve campaign performance. Oracle Cloud Marketplace is a one-stop shop for Oracle customers seeking trusted business applications and services offering unique solutions, including ones that extend Oracle Fusion Cloud Applications. Infobip’s communication channels will enable businesses to deliver conversational experiences across many sectors including banking and financial services, retail and ecommerce, and hospitality and leisure. Through Infobip’s collaboration, Oracle users will gain customer insights, enabling them to

Global CIOs geared up to scale AI but organizations aren’t as ready25.4.2024 05:00:00 CEST | Press release

AI is the CIO’s top priority, according to findings of Lenovo’s third annual global CIO report. Inside the Tornado: How AI is Reshaping Corporate IT Today, reveals that while CIOs need to adopt and scale AI urgently, their ambitions are threatened by speed, security, and other organizational functions lagging in AI readiness. In a stark contrast to previous years, CIOs are tabling non-traditional responsibilities to sharpen their focus on core IT functions. Slightly more than half (51%) of CIOs feel AI/ML is an urgent priority to address, matched only by cybersecurity. This urgency is directly correlated to the pressure that CIOs are under to drive business impact, rather than operational maintenance and preservation. 84% of CIOs revealed they are being evaluated on business outcome metrics more than ever before. “Today’s CIOs are working in a tornado of innovation. After years of IT expanding into non-traditional responsibilities, we’re now seeing how AI is forcing CIOs back to their

Mundipharma acquires all assets and rights related to REZZAYO ® (rezafungin) , reinforcing continued commitment to management of infectious diseases and specialty care therapeutic area24.4.2024 22:01:00 CEST | Press release

Mundipharma* today announced the acquisition of all assets and rights related to rezafungin globally from Cidara Therapeutics. This provides Mundipharma with global ownership of rezafungin including ongoing development and distribution. Rezafunginis a novel once-weekly echinocandin indicated for the treatment of invasive candidiasis in adults.1 Invasive candidiasis, is a severe, life-threatening infection of the bloodstream and/or deep/visceral tissues.2,3 It affects seriously ill people, especially those with a weakened immune systemand the mortality rate can be 40%4 or more.5,6 It can place a large burden on the healthcare system, with the potential for extended treatment regimens and long hospital stays.6 Over the last 15 years, there have been no new treatments and morbidity and mortality rates remain largely the same, indicating the need for alternative treatment options.7,8 “This acquisition places Mundipharma in the best position to realise the full potential of rezafungin inclu

HiddenA line styled icon from Orion Icon Library.Eye